AKT1 and hepatocellular carcinoma: Furthermore, recent evidence identifies mechanisms of feedback activation of the AKT-mTORC1 pathway (a major oncogenic pathway central to the processes of hCC development) in the setting of enzalutamide-treated HCCs [126].